Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
16 September, 2014 22:27 IST
News
Lupin can garner sales of USD 30 mn from generic Yasmin: Angel Broking
Source: IRIS Exclusive (20-DEC-12)
Comments  |  Post Comment

Angel Broking has maintained 'Buy' on Lupin with a price target of Rs 655 in its report dated Dec. 20, 2012.

Pharma major, Lupin, announced that its subsidiary Lupin Pharmaceuticals has received final approval for its Drospirenone and Ethinyl Estradiol Tablets, 3 mg / 0.03 mg from the United States Food and Drugs Administration (FDA) to market a generic version of BayerHealthcare's (Bayer) Yasmin Tablets 3 mg / 0.03 mg.

Lupin's Drospirenone and Ethinyl Estradiol Tablets are the AB rated generic equivalent of Bayer's Yasmin Tablets 3 mg /0.03 mg. Yasmin Tablets had annual US sales of approximately USD 275 million (IMS MAT Sept 2012 sales). On a conservative side the company can garner sales of around USD 30 million and net profit of USD 9-10 million.

Click here to view full report


Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.



Lupin Limited   (Q,N,C,F)*


News
NTPC signs MoU with AP govt for 1,000 MW solar power projects - 16-Sep-2014 18:30
Jet Airways signs contract for training centre operation services with CAE - 16-Sep-2014 18:06
Morgan Stanley buys 1.15% stake in Future Retail - 16-Sep-2014 18:05
'Buy' J&K Bank; target Rs 170: ICICIdirect - 16-Sep-2014 17:50
Maruti's Manesar production crosses 2.5 mn mark - 16-Sep-2014 17:28
Aurobindo gets USFDA nod for Amoxicillin for Oral Suspension - 16-Sep-2014 16:28
CRISIL downgrades Venus Remedies - 16-Sep-2014 16:23
Angel Broking remains neutral on Lupin - 16-Sep-2014 16:17
Usha Martin board approves right issue - 16-Sep-2014 16:06
KKR extends financing to GMR Holdings - 16-Sep-2014 15:57
Axis Bank joins ETC Implementation plan of road transport & highways ministry - 16-Sep-2014 15:48
more...
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
By: Carol | 28 December 2012 Reply | Forward | Report Abuse 
Yasmin might have generated lots of sales, but that has more to do with heavy advertising than the quality of the pill itself. In fact, the FDA says that there might be a significantly higher chance that woman who take birth control pills with drospirenone, such as Yaz, Yasmin and Ocella, will experience a blood clot. http://www.publichealthwatchdog.com/fda-study-links-yaz-yasmin-and-other-similar-birth-control-pills-to-increased-risk-of-blood-clots/
 Post Comment
Name Email
Comment
Security Code type   c9vhq9 into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer